Smartphone acquisition and use at age 13 and health outcomes at age 14
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 08:17 ET (30-Oct-2026 12:17 GMT/UTC)
Researchers found postoperative delirium was strongly associated with long-term cognitive decline and the effect was not explained by rehospitalizations, highlighting the long-term impact of delirium on brain health
Researchers found postoperative delirium was strongly associated with long-term cognitive decline and the effect was not explained by rehospitalizations, highlighting the long-term impact of delirium on brain health.
The Academy of Nutrition and Dietetics is proud to welcome six new registered dietitian nutritionists to the program of trained media experts who help translate nutrition science into clear, consumer-friendly information, including Pennington Biomedical Research Center’s Dr. Jacob Mey. Dr. Mey is the first spokesperson from Pennington Biomedical and the only current Academy Spokesperson based in Louisiana.
New research on older Floridians reveals a striking disparity in melanoma outcomes. Men experience roughly twice as many melanoma-related deaths as women. Non-Hispanic and white populations also face higher rates of melanoma diagnosis and death than Hispanic groups. Researchers suggest differences likely reflect a combination of higher UV exposure, lower sun-protective behaviors and screening in men, disparities in access to care, and possible biological sex differences in immune response. The findings underscore an uneven burden and urgent need for targeted prevention and early detection.
Institut Pasteur is launching ACT-CHIK (Accelerating Clinical Trials for CHIKungunya Vaccine in Africa), a major four-year research project funded by the Global Health EDCTP3 Joint Undertaking under the European Union's Horizon Europe program. With €15.3 million in EU funding, ACT-CHIK will advance the clinical development of MV-CHIK — a measles-virus-based chikungunya vaccine originally developed at Institut Pasteur — through a large-scale Phase Ib/III clinical trial in four African countries, while preparing for technology transfer to an African vaccine manufacturer.